69 studies found for:    Alkermes | United States
Show Display Options
Rank Status Study
1 Recruiting A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole Lauroxil
2 Recruiting A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
3 Recruiting A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Conditions: Schizophrenia;   Alcohol Use Disorder
Interventions: Drug: Samidorphan + olanzapine (ALKS 3831);   Drug: Placebo
4 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
5 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Condition: Major Depressive Disorder
Interventions: Drug: High Dose ALKS 5461;   Drug: Low Dose ALKS 5461;   Drug: Placebo
6 Completed A Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Samidorphan (Low Dose);   Drug: Samidorphan (Medium Dose);   Drug: Samidorphan (High Dose);   Drug: Placebo;   Drug: Olanzapine
7 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ALKS 9072;   Drug: Placebo
8 Completed An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole Lauroxil
9 Recruiting A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Condition: Schizophrenia,
Interventions: Drug: ALK3831;   Drug: Olanzapine;   Drug: Placebo
10 Completed A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461
11 Recruiting A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Condition: Schizophrenia
Interventions: Drug: ALKS 3831;   Drug: Olanzapine
12 Recruiting A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: ALKS 3831
13 Completed Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
Condition: Renal Impairment
Intervention: Drug: ALKS 5461
14 Recruiting Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
Condition: Opioid Use Disorder
Interventions: Drug: NTX/BUP;   Drug: NTX/PBO-B;   Drug: PBO-N/PBO-B
15 Completed ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
Condition: Opioid-induced Constipation
Interventions: Drug: ALKS 37;   Drug: Placebo
16 Enrolling by invitation A Long-Term Safety Study of ALKS 5461
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461
17 Completed A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Condition: Schizophrenia
Interventions: Drug: ALKS 9072, Low;   Drug: ALKS 9072, High
18 Completed A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
19 Enrolling by invitation An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Condition: Schizophrenia
Interventions: Drug: ALKS 9072, Low Dose;   Drug: ALKS 9072, High Dose
20 Completed ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
Condition: OIC
Interventions: Drug: ALKS 37;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years